U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146087) titled 'Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis' on Aug. 20.
Brief Summary: The goal of this clinical trial is to learn if intravenous infusion of allogeneic mesenchymal stem cell (MSC)-derived exosomes can slow disability progression and improve neurological function in adults with progressive multiple sclerosis (MS). The trial will also evaluate the safety and tolerability of repeated exosome infusions.
The main questions it aims to answer are:
Does MSC-derived exosome therapy reduce disability progression as measured by the Expanded Disability Status Scale (EDSS)?
Does MSC-derived ex...